Effects of IL-1 beta inhibition on vascular inflammation in TET2 clonal hematopoiesis
Description: PROJECT NARRATIVE Clonal hematopoiesis is a common, age-related condition which increases the risk for multiple health issues including heart disease and cancer, with specific sub-types, such as TET2 clonal hematopoiesis, conferring particularly high risk for heart attacks. Our clinical trial will provide critical insights as to why patients with TET2 clonal hematopoiesis have a high risk of heart attacks by examining the effects of a medication, which modulates the immune system, on inflammation of the blood vessels and clonal hematopoiesis. Thus, our study will inform strategies to prevent heart attacks and reduce clonal hematopoiesis among an aging population.
Funding type: research
Funder scheme: R01
Start date: 2025-01-01
End date: 2030-05-31
Investigator: MICHAEL HONIGBERG
Institution: MASSACHUSETTS GENERAL HOSPITAL
Funded outputs count: 15
Funder award ID: R01HL173028
OpenAlex ID: G9000864106